US 12,186,368 B2
Compositions and methods for treatment of protease mediated disease
Michael E. Selsted, Pasadena, CA (US); and Dat Q. Tran, Alhambra, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Mar. 20, 2020, as Appl. No. 16/825,221.
Application 16/825,221 is a continuation of application No. 15/135,060, filed on Apr. 21, 2016, granted, now 10,603,356, issued on Mar. 31, 2020.
Application 15/135,060 is a continuation of application No. 14/491,661, filed on Sep. 19, 2014, granted, now 9,346,866, issued on May 24, 2016.
Application 14/491,661 is a continuation of application No. 13/486,548, filed on Jun. 1, 2012, granted, now 10,512,669, issued on Dec. 4, 2019.
Claims priority of provisional application 61/492,753, filed on Jun. 2, 2011.
Prior Publication US 2020/0333024 A1, Oct. 22, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 9/00 (2006.01); A61K 38/10 (2006.01); A61K 38/12 (2006.01); A61K 38/55 (2006.01); C07K 14/47 (2006.01); F01P 5/04 (2006.01); F24F 5/00 (2006.01); F24F 6/16 (2006.01); B63J 3/00 (2006.01)
CPC A61K 38/1729 (2013.01) [A61K 9/0053 (2013.01); A61K 38/10 (2013.01); A61K 38/12 (2013.01); A61K 38/55 (2013.01); C07K 14/4723 (2013.01); F01P 5/04 (2013.01); F24F 5/0007 (2013.01); F24F 6/16 (2013.01); B63J 2003/002 (2013.01); F01P 2005/046 (2013.01); F24F 2203/1028 (2013.01); F24F 2203/1076 (2013.01)] 15 Claims
 
1. A method of inhibiting a metalloprotease and a cysteine protease in a subject in need thereof, comprising:
injectably administering to the subject in need thereof a θ-defensin in an amount effective to inhibit the metalloprotease and the cysteine protease; wherein the θ-defensin is administered intravenously, subcutaneously, or intraperitoneally; and wherein the administration reduces TNF-alpha mediated inflammation in the subject.